Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Pacira

Status and phase: Terminated; Phase 2

Conditions: Osteoarthritis of the Shoulder; Adhesive Capsulitis

Treatments: Drug: FX006; Drug: Normal Saline

Study type: Interventional

Funder types: Industry

Identifiers

NCT04160091

FX006-2018-016

Details and patient eligibility

About

This is a double-blind study to evaluate the efficacy and safety of FX006 in patients with glenohumeral osteoarthritis (OA) or shoulder adhesive capsulitis (AC).

Full description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in separate cohorts of patients with a documented history of either glenohumeral OA or shoulder AC. Glenohumeral OA and shoulder AC patients will be randomized to receive a single intra-articular injection of either FX006 or placebo (saline) in a 1:1 ratio to the index shoulder with a 24-week Treatment Evaluation Period. Glenohumeral OA patients will be stratified by Baseline average daily shoulder pain with movement score according to the following classifications: 5.0 to <7.0 or ≥7.0 to 9.0 (0 to 10 numeric rating scale [NRS]). Shoulder AC patients will be stratified by Baseline average daily shoulder pain with movement score according to the following classifications: 5.0 to <7.0 or ≥7.0 to 9.0 (0 to 10 NRS), and by pain duration since onset (1 to 3 months, inclusive, or >3 to ≤6 months). A Home Exercise Program will be implemented 3 days following injection for shoulder AC patients.

Enrollment: 19 patients

Sex: All

Ages: 35 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Glenohumeral OA:

• Male or female, 35 to 80 years of age, inclusive, on the day of consent.
• Painful symptoms associated with OA of the index glenohumeral joint for ≤3 months prior to the Screening Visit.
• Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at the Screening Visit.

Shoulder AC:

• Male or female, 35 to 80 years of age, inclusive, on the day of consent.
• Pain associated with AC of the index joint for ≥1 month but ≤ 6 months prior to the Screening Visit.
• Limitations on both active and passive ROM ≥25% in at least 2 directions (e.g., forward flexion, abduction, and internal and external rotation assessed in a standardized protocol) compared with the contralateral shoulder or with normal values.
• No X-ray evidence of OA of the index shoulder (axillary view and true anterior-posterior view) at the Screening Visit.
• Agrees to complete a standardized, protocol-specified shoulder Home Exercise Program (HEP) starting 3 days after injection until the End of Study (EOS) Visit.

Both:

• Written consent to participate in the study
• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
• (BMI) ≤ 40 kg/m2
• Average daily mean shoulder pain with movement score ≥5.0 and ≤9.0 in the index shoulder (0 to 10 NRS) using the average daily ratings for at least 5 out of the 7 days prior to Day 1.
• Shoulder pain present >15 days in the month prior to the Screening Visit
• Willing to complete a washout of protocol-specified excluded medications 7 days prior to Day 1 and abstain from use of protocol-specified excluded medications throughout the study
• Willing to abstain from nonpharmacological therapies for the index joint for 2 weeks prior to Day 1 and throughout the study.

Exclusion criteria

• Has both glenohumeral OA and shoulder AC
• Has bilateral AC
• Has bilateral glenohumeral OA with glenohumeral OA pain of the shoulder contralateral to the index shoulder >3.0 (0 to 10 NRS) within 1 month prior to the Screening Visit
• Has a history of arthritis in other joints of the index shoulder (as confirmed by medical history and physical exam)
• Has a history or suspicion of full thickness rotator cuff tear in the index shoulder within 6 months of the Screening Visit
• Has symptomatic partial rotator cuff tear, tendinopathy, tendonitis, or bursitis in the index shoulder within 6 months of the Screening Visit
• Has a subchondral bone insufficiency fracture or humeral head necrosis/collapse in the index shoulder
• Shoulder AC patients only: Has a history of shoulder surgery or radiotherapy
• Glenohumeral OA patients only: Has a previous shoulder injury with functional limitation ≥1 month or surgery within 52 weeks of the Screening Visit
• Has an index shoulder with major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, or primary osteochondromatosis, or a history of avascular necrosis with secondary OA
• Has current or history of infection in the index shoulder or current skin infection at injection site
• Has a concurrent chronic pain condition with a pain score >3.0 (0 to 10 NRS) within 1 month prior to the Screening Visit
• Has a history or current evidence of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease, systemic lupus erythematosus, calcium pyrophosphate dihydrate crystal deposition disease (CPPD), or other autoimmune diseases
• Has any planned surgeries in the upper limbs during the study or any other surgery during the study that would require use of a restricted medication
• Has surgical hardware or other foreign body present in the index shoulder
• Has received an IA corticosteroid of any joint within 3 months of the Screening Visit
• Has received an IA treatment of the index shoulder with any of the following agents within 6 months of the Screening Visit
• Has received intravenous (IV), intrabursal, intratendinous, intramuscular (IM) or epidural corticosteroids within 3 months of the Screening Visit
• Has received oral corticosteroids within 1 month of the Screening Visit
• Has received inhaled, intranasal, or topical corticosteroids within 2 weeks of the Screening Visit
• Has had significant changes to lifestyle with regard to physical activity and lifestyle within 1 month of the Screening Visit or any planned changes throughout the duration of the study
• Has known hypersensitivity to TA or PLGA
• Has laboratory evidence of infection with (HIV), a positive test for hepatitis B surface antigen (HBsAg), or positive serology for hepatitis C virus (HCV) with positive test for HCV ribonucleic acid
• Has an electrocardiogram (ECG) abnormality
• Has uncontrolled diabetes as indicated by a hemoglobin A1c of >8% (>59 mmol/mol).
• Has a history of sarcoidosis or amyloidosis
• Has a history of or active Cushing's syndrome
• Has used chemotherapeutic agents, immunomodulators, or immunosuppressants within 5 years of the Screening Visit
• Has current or history of malignancy within 5 years prior to the Screening Visit, except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ that has been treated successfully.
• Has active substance use disorder or history of substance use disorder within 12 months prior to the Screening Visit
• Has received a live or live attenuated vaccine within 3 months of the Screening Visit
• Has used any other investigational drug, biologic, or device within 3 months of the Screening Visit
• Has any infection requiring IV antibiotics 4 weeks prior to Day 1 or oral antibiotics 2 weeks prior to Day 1
• Has a contraindication to the use of acetaminophen
• Is a female that is pregnant or nursing or plans to become pregnant during the study; or is a male who plans to inseminate a partner or donate sperm during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

19 participants in 4 patient groups, including a placebo group

FX006 32mg in Glenohumeral OA Population

Experimental group

Description:

Single intra-articular (IA) injection

Treatment:

Drug: FX006

Normal Saline in Glenohumeral OA Population

Placebo Comparator group

Description:

Single intra-articular (IA) injection

Treatment:

Drug: Normal Saline

FX006 32mg in Adhesive Capsulitis Population

Experimental group

Description:

Single intra-articular (IA) injection

Treatment:

Drug: FX006

Normal Saline in Adhesive Capsulitis Population

Placebo Comparator group

Description:

Single intra-articular (IA) injection

Treatment:

Drug: Normal Saline